Conduct Phase III CT, the CDSCO Panel instructs Biocon Biologics regarding the anti-cancer drug nimuzumab.

Published Date: 14 Jul 2023

New Delhi: The Subject Expert noted that there are no compelling data available for the suggested additional indication for the medication Nimutuzumab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.

2.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

3.

We Don't Always Know What's 'Best' for Our Patients

4.

Should the UK introduce targeted prostate cancer screening? The case for and against

5.

Germline Profiling May Improve Risk Stratification in t-MNs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot